Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92833
UPID:
JARD2_HUMAN
Alternative names:
Jumonji/ARID domain-containing protein 2
Alternative UPACC:
Q92833; A8K9Z6; B7Z5S5; B7Z8L0; Q5U5L5; Q86X63
Background:
Protein Jumonji, also known as Jumonji/ARID domain-containing protein 2, is a pivotal regulator in embryonic development, influencing heart and liver formation, neural tube fusion, and hematopoiesis. It functions as an accessory unit for the PRC2 complex, facilitating histone H3K27 trimethylation, essential for DNA binding and stem cell differentiation.
Therapeutic significance:
Linked to developmental delay with variable intellectual disability and dysmorphic facies, understanding the role of Protein Jumonji could open doors to potential therapeutic strategies.